90 related articles for article (PubMed ID: 11752085)
21. In vitro antineoplastic activity of a novel lanthionine-containing peptide.
Zheng H; Fink D; Li H; Jiang X; Aebi S; Law P; Goodman M; Howell SB
Clin Cancer Res; 1997 Aug; 3(8):1323-30. PubMed ID: 9815815
[TBL] [Abstract][Full Text] [Related]
22. Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results.
Raderer M; Hamilton G; Kurtaran A; Valencak J; Haberl I; Hoffmann O; Kornek GV; Vorbeck F; Hejna MH; Virgolini I; Scheithauer W
Br J Cancer; 1999 Feb; 79(3-4):535-7. PubMed ID: 10027326
[TBL] [Abstract][Full Text] [Related]
23. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice.
Corbett TH; Roberts BJ; Leopold WR; Peckham JC; Wilkoff LJ; Griswold DP; Schabel FM
Cancer Res; 1984 Feb; 44(2):717-26. PubMed ID: 6692374
[TBL] [Abstract][Full Text] [Related]
24. Intratumoral chemotherapy with a sustained-release drug delivery system inhibits growth of human pancreatic cancer xenografts.
Smith JP; Stock E; Orenberg EK; Yu NY; Kanekal S; Brown DM
Anticancer Drugs; 1995 Dec; 6(6):717-26. PubMed ID: 8845483
[TBL] [Abstract][Full Text] [Related]
25. Sensitivity of proliferating cultured murine pancreatic tumor cells to selected antitumor agents.
Wilkoff LJ; Dulmadge EA
J Natl Cancer Inst; 1986 Nov; 77(5):1163-9. PubMed ID: 3464801
[TBL] [Abstract][Full Text] [Related]
26. [In vitro evaluation of potentially effective gemcitabine combination therapy for exocrine pancreatic carcinoma].
Kreil A; Bauer J; Scheithauer W
Acta Med Austriaca; 1999; 26(3):93-100. PubMed ID: 10520377
[TBL] [Abstract][Full Text] [Related]
27. Absence of therapeutic efficacy of the somatostatin analogue lanreotide in advanced primary hepatic cholangiocellular cancer and adenocarcinoma of the gallbladder despite in vivo somatostatin-receptor expression.
Fiebiger WC; Scheithauer W; Traub T; Kurtaran A; Gedlicka C; Kornek GV; Virgolini I; Raderer M
Scand J Gastroenterol; 2002 Feb; 37(2):222-5. PubMed ID: 11843061
[TBL] [Abstract][Full Text] [Related]
28. [DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting.
Tatsi A; Maina T; Cescato R; Waser B; Krenning EP; de Jong M; Cordopatis P; Reubi JC; Nock BA
Eur J Med Chem; 2014 Feb; 73():30-7. PubMed ID: 24378707
[TBL] [Abstract][Full Text] [Related]
29. Identification of pancreatic cancer stem cells and selective toxicity of chemotherapeutic agents.
Adikrisna R; Tanaka S; Muramatsu S; Aihara A; Ban D; Ochiai T; Irie T; Kudo A; Nakamura N; Yamaoka S; Arii S
Gastroenterology; 2012 Jul; 143(1):234-45.e7. PubMed ID: 22510202
[TBL] [Abstract][Full Text] [Related]
30. Anacardic acid inhibits pancreatic cancer cell growth, and potentiates chemotherapeutic effect by Chmp1A - ATM - p53 signaling pathway.
Park M; Upton D; Blackmon M; Dixon V; Craver S; Neal D; Perkins D
BMC Complement Altern Med; 2018 Feb; 18(1):71. PubMed ID: 29463243
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and biological evaluation of somatostatin-based radiopeptides.
Ginj M; Schmitt JS; Chen J; Waser B; Reubi JC; de Jong M; Schulz S; Maecke HR
Chem Biol; 2006 Oct; 13(10):1081-90. PubMed ID: 17052612
[TBL] [Abstract][Full Text] [Related]
32. Somatostatin receptor-targeted anti-cancer therapy.
Sun LC; Coy DH
Curr Drug Deliv; 2011 Jan; 8(1):2-10. PubMed ID: 21034425
[TBL] [Abstract][Full Text] [Related]
33. Evidence of
Marenco M; Lodola L; Persico MG; Frangipane V; Facoetti A; Aprile C; Hodolič M
Curr Pharm Biotechnol; 2018; 19(9):754-759. PubMed ID: 30160211
[TBL] [Abstract][Full Text] [Related]
34. Lanreotide-induced modulation of 5-fluorouracil or mitomycin C cytotoxicity in human colon cancer cell lines: a preclinical study.
Tesei A; Ricotti L; De Paola F; Casini-Raggi C; Barzanti F; Frassineti GL; Zoli W
J Chemother; 2000 Oct; 12(5):421-30. PubMed ID: 11128563
[TBL] [Abstract][Full Text] [Related]
35. New somatostatin-drug conjugates for effective targeting pancreatic cancer.
Ragozin E; Hesin A; Bazylevich A; Tuchinsky H; Bovina A; Shekhter Zahavi T; Oron-Herman M; Kostenich G; Firer MA; Rubinek T; Wolf I; Luboshits G; Sherman MY; Gellerman G
Bioorg Med Chem; 2018 Jul; 26(13):3825-3836. PubMed ID: 30017114
[TBL] [Abstract][Full Text] [Related]
36. Transfection of SSTR-1 and SSTR-2 inhibits Panc-1 cell proliferation and renders Panc-1 cells responsive to somatostatin analogue.
Li M; Zhang R; Li F; Wang H; Kim HJ; Becnel L; Yao Q; Chen C; Fisher WE
J Am Coll Surg; 2005 Oct; 201(4):571-8. PubMed ID: 16183496
[TBL] [Abstract][Full Text] [Related]
37. Application of human pancreatic carcinoid BON cells for receptor-targeted drug development.
Sun L; Morris LM; Luo J; Mackey LV; Leslie JS; Franko-Tobin LG; Fuselier JA; LePage KT; Coy DH
J Drug Target; 2011 Sep; 19(8):666-74. PubMed ID: 21083509
[TBL] [Abstract][Full Text] [Related]
38. Hyperthermia Enhances Efficacy of Chemotherapeutic Agents in Pancreatic Cancer Cell Lines.
Maurici CE; Colenbier R; Wylleman B; Brancato L; van Zwol E; Van den Bossche J; Timmermans JP; Giovannetti E; Mori da Cunha MGMC; Bogers J
Biomolecules; 2022 Apr; 12(5):. PubMed ID: 35625581
[TBL] [Abstract][Full Text] [Related]
39. hSSTR2 expression and octreotide treatment reverses multidrug resistance of BxPC-3 human pancreatic cancer cells.
Sui C; Ma Q; Nan K; Xiao J; Suo A; Sha H; Zhao L
Oncol Rep; 2009 Dec; 22(6):1391-6. PubMed ID: 19885591
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxicity of several chemotherapeutic agents in a human pancreatic cancer cell line (Colo-357).
Cadman E; Benz C
Cancer Treat Rep; 1984 Feb; 68(2):429-30. PubMed ID: 6697332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
